Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center’s Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH). This enables the initiation of [...]
Archive for September, 2008
Clinical Trial Protocol Against Cancer Therapy Side Effects (Mucositis) Approved
Posted by admin in September 4th 2008
RSS
Recent Articles
-
- Successful Treatment of Cardiovascular Disease Using Stem Cells
- Revolutionary Alternative to Liposuction that Permanently Melts Away Fat
- SunTech Medical Introduces Next Generation of OEM NIBP Module
- Clinical Trial Protocol Against Cancer Therapy Side Effects (Mucositis) Approved
- Investigational Device for Patients With Lumbar Spinal Stenosis
- Neutrogena Partnership For Skin Health Taps Malin Akerman to Educate About Skin Cancer Detection
- Scotsmen Set Out to Raise Awareness of Rare Syndrome on a Journey Across America
- Nintendo and Starlight’s New Fun Centers Featuring Wii Give Sick Children a Boost
- Nerve Cells Derived from Embryonic Stem Cells and Transplanted into Mice May Lead to Improved Brain Treatments
- Advantage Medical Devices Receives FDA Clearance for VantageCath
- VascuSeal Vascular Sealant System
- FATAL CARE: Survive In The U.S. Health System
- Beckman Coulter Acquires Rights to Hepatitis C Virus
- Medtronic Announces FDA Clearance of New OneTouch UltraLink Blood Glucose Meter
- DynaMed Systems Obtains FDA Approval to Study Its Traxon Spinal Cord Repair Stimulation System in Acute Spinal Cord Injured (SCI) Patients
